Purdue Pharma L.P.
Case Number:
7:19-bk-23649
Court:
Nature of Suit:
Firms
- Phillips Lytle
- Brown & Connery
- Ice Miller
- Foley & Lardner
- Skadden Arps
- Tarter Krinsky
- Teitelbaum Law Group
- Duane Morris
- Hagens Berman
- Simmons Hanly
- Motley Rice
- Debevoise & Plimpton
- Bielli & Klauder
- Godfrey & Kahn
- Himes Petrarca
- Manatt Phelps
- Wachtell Lipton
- Hurwitz Fine
- Morris Nichols
- Gilbert LLP
- BatesCarey
- Lowe Stein
- Arnold & Porter
- Archer & Greiner
- Katsky Korins
- Brown Rudnick
- Gage Spencer & Fleming
- Pashman Stein
- Hogan Lovells
- Katten Muchin
- Morrison & Foerster
- Doshi Legal Group
- Willkie Farr
- Buchalter LLP
- FBT Gibbons
- Terrell Hogan
- Goodwin Procter
- Davis Polk
- Pillsbury Winthrop
- ArentFox Schiff
- Crowell & Moring
- McDermott Will & Schulte
- Gertz & Rosen
- Consovoy McCarthy
- Porteous Hainkel
- Rothstein Mandell
- Caplin & Drysdale
- Jones Day
- Porter Hedges
- Kirkland & Ellis
- Bentley & Bruning
- ASK LLP
- Dentons
- Faegre Drinker
- Joseph Hage
- Doster Ullom
- Marino Tortorella
- White & Case
- Boies Schiller
- HSF Kramer
- Spangenberg Shibley
- Cuneo Gilbert
- MoloLamken
- Morgan Lewis
- Blitman & King
- WilmerHale
- Latham & Watkins
- Akin Gump
- McElroy Deutsch
- Jenner & Block
- Reed Smith
- Kobre & Kim
- O'Melveny & Myers
- Seyfarth Shaw
- Alston & Bird
- King & Spalding
- Troutman
- Stevens & Lee
- Mintz Levin
- WestLoop Law
- Miller Nash LLP
- Cronin Fried
- Loeb & Loeb
- Diamond McCarthy
- Slevin & Hart
- Plevin & Turner
- Schenck Price
- Bialson Bergen
- Martin S. Rapaport
- Akerman LLP
- Fox Swibel
- Lerner Arnold
- Burke Warren
- Shook Hardy
- Sherrard Roe
- Taft Stettinius
- Sahn Ward
- Cleary Gottlieb
- Simpson Thacher & Bartlett
- Napoli Shkolnik
- D. Miller & Associates
- McGrail & Bensinger
- Marcus & Shapira
- Quinn Emanuel
- Pachulski Stang
- UB Greensfelder
- Wilk Auslander
- Shafferman & Feldman
- Squire Patton
- Hughes Socol
- Robins Kaplan
- Blank Rome
- Keller Rohrback
- Ballard Spahr
- Keller Postman
- Webb Law Firm
- Kleinberg Kaplan
- Clifford Law Offices
- Barack Ferrazzano
- Stutzman Bromberg
- Levenfeld Pearlstein
- MacElree Harvey
- Klehr Harrison
- Pullman & Comley
- Mehri & Skalet
- Tate Law Group LLC
- Lowey Dannenberg
- Williams Mullen
- Waldrep Wall
- Barclay Damon
- Dechert LLP
- Ifrah Law
- Seward & Kissel
- Calfee Halter
- White Coleman & Associates
- Miller Shah
- Susman Godfrey
- O'Brien Belland
- Binder & Schwartz
- Carter Ledyard
- Shipman & Goodwin
- Henrichsen Law Group
- Haug Partners
- Hobbs Straus
- Mayer Brown
- Milbank LLP
Companies
- Teamsters Local 456
- Henry Schein Inc.
- Cencora Inc.
- Bristol-Myers Squibb Co.
- Hikma Pharmaceuticals PLC
- Giant Eagle Inc.
- McKesson Corp.
- BDO LLP
- Otis Worldwide Corp.
- Johnson & Johnson
- Liberty Mutual Insurance Group
- FTI Consulting Inc.
- Kodiak Area Native Association
- Ranbaxy
- PRA Health Sciences Inc.
- Ascent Pharmaceuticals Inc.
- Blue Cross Blue Shield Association
- Aleutian Pribilof Islands Association Inc.
- KVK Tech Inc.
- Collegium Pharmaceutical Inc.
- Noramco Inc.
- Endo International PLC
- Impax Laboratories, Inc.
- Omnicare Inc.
- Bausch Health Cos. Inc.
- Province LLC
- Sandoz International GmbH
- Avrio Health LP
- Nardello & Co. LLC
- DuPont de Nemours Inc.
- Hain Capital Group LLC
- United Parcel Service Inc.
- Express Scripts Holding Co.
- CVS Health Corp.
- Ironshore Inc.
- Amneal Pharmaceuticals Inc.
- Sun Pharmaceutical Industries Ltd.
- Loblaw Cos.
- Tucson Medical Center
- TR Capital Management LLC
- Viatris Inc.
- The Cigna Group
- Alaska Native Tribal Health Consortium
- Anda Inc.
- Walmart Inc.
- AXA XL Ltd.
- Allergan PLC
- BDO USA LLP
- Rubris Inc.
- AlixPartners LLP
- Purdue Pharma LP
- United Food & Commercial Workers International Union
- ASM Capital LP
- SAP AG
- Apria Healthcare Group
- Cardinal Health Inc.
- Arcadia Consumer Healthcare
- International Union Of Operating Engineers
- Old Republic Insurance Co.
- Oracle Corp.
- Thermo Fisher Scientific Inc.
- Verita Global LLC
- Houlihan Lokey Inc.
- American Federation of Labor & Congress of Industrial Organizations
- Jefferies Financial Group Inc.
- Teva Pharmaceutical Industries Ltd.
Government Agencies
- Pension Benefit Guaranty Corp.
- Missouri Department of Revenue
- U.S. District Court for the District of Columbia
- Tennessee Attorney General's Office
- Pala Band of Mission Indians
- Seldovia Village Tribe
- Nez Perce Tribe
- Town of Ramapo, New York
- Jamestown S'Klallam Tribe
- St. Regis Mohawk Tribe
- State of Indiana
- City of Bayonne, New Jersey
- Washington State Department of Revenue
- Colorado Attorney General's Office
- Port Gamble S'Klallam Tribe
- Borough of Paramus, New Jersey
- State of Nevada
- Northwestern Band of the Shoshone Nation
- Town of Babylon, New York
- Town of Brookhaven, New York
- New York Department of Financial Services
- Town of Hempstead, New York
- Commonwealth of Massachusetts
- Hopi Tribe
- Suquamish Tribe
- Ohio Attorney General's Office
Sectors & Industries:
-
November 09, 2021
Purdue Agrees Not To Finalize Ch. 11 Plan Until Appeals Done
A New York bankruptcy judge said Tuesday that a stay of the implementation of Purdue Pharma's Chapter 11 plan pending appeals was unnecessary after Purdue agreed not to take the plan's final steps until after the first round of appeals are decided.
-
October 25, 2021
Purdue Opposes Requests To Delay Ch. 11 Plan For Appeals
Purdue Pharma LP is arguing that delaying the consummation of its Chapter 11 plan to allow appeals to be resolved first would needlessly delay the distribution of billions of dollars for opioid abatement efforts while there was no danger of prejudice to the appellants.
-
October 20, 2021
Purdue Asks To Pay Ch. 11 Costs Of Government Committees
Bankrupt drugmaker Purdue Pharma LP asked for permission from a New York judge late Tuesday to pay $12.4 million in fees and expenses incurred by committees of nonconsenting state and local governments during a Chapter 11 plan mediation process.
-
October 14, 2021
Purdue Ch. 11 Plan Challenges Won't Hit 2nd Circ. Right Away
A New York bankruptcy judge on Thursday denied a motion from parties appealing the confirmation of Purdue Pharma's Chapter 11 plan to bypass the normal appellate channels and bring their arguments directly to the Second Circuit.
-
October 12, 2021
Purdue Ch. 11 Appeals To Be Heard Before Plan Effective Date
A Manhattan federal judge said Tuesday that she would hear oral arguments in the appeals of Purdue Pharma's Chapter 11 plan on Nov. 30 after adopting a briefing schedule proposed by the debtors and saying that she is committed to an expedited appeal process.
-
October 08, 2021
Canadian Creditors Seek Direct Appeal Of Purdue Ch. 11 Plan
A group of Canadian creditors told a New York bankruptcy judge that they support consolidating the appeals for Purdue Pharma's Chapter 11 plan and that those appeals should be allowed to move directly to the Second Circuit.
-
September 24, 2021
California AG Announces Appeal Of Purdue Ch. 11 Plan
California Attorney General Rob Bonta on Friday became the latest attorney general to announce an appeal of the approval of Purdue Pharma's Chapter 11 plan, saying the OxyContin maker's former owners in the Sackler family must be held accountable for their part in the opioid crisis.
-
September 22, 2021
US Trustee Challenges Constitutionality Of Purdue Releases
The nondebtor, third-party releases included in Purdue Pharma's Chapter 11 plan are unconstitutional, the U.S. Trustee's Office has argued, asking a New York bankruptcy judge to wait until a higher court rules on the federal watchdog's challenge to the releases.
-
September 16, 2021
US Trustee To Appeal Sackler Releases In Purdue Ch. 11
The U.S. Trustee's Office has told a New York bankruptcy judge it will appeal his order approving Purdue Pharma's Chapter 11 plan, saying the plan's liability releases for Purdue's Sackler family now-former owners go beyond the law and undermine confidence in the system.
-
September 13, 2021
Purdue Pharma Gets OK For $7.1M In Exec Incentives
A New York bankruptcy judge gave Purdue Pharma permission Monday to make incentive payments of up to $7.1 million to its top executives, rejecting arguments that the executives had not done enough to clean up the company's corporate culture.